About this Journal Submit a Manuscript Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 314283, 19 pages
http://dx.doi.org/10.1100/2012/314283
Review Article

LDL-Apheresis: Technical and Clinical Aspects

1Institute for Blood Purification, Saar, 66424 Homburg, Germany
2Formerly Main Hospital Darmstadt, 64283 Darmstadt, Germany
3Laboratory of Medicine, 66386 St. Ingbert, Germany
4Inselklinik Heringsdorf GmbH, 17424 Seeheilbad Heringsdorf, Germany

Received 30 October 2011; Accepted 3 January 2012

Academic Editor: Kathleen M. Botham

Copyright © 2012 Rolf Bambauer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Bambauer, R. Latza, M. R. Lentz, et al., Therapeutic Plasma Exchange and Selective Plasma Separation Methods. Fundamental Technologies, Pathology and Clinical Results, Pabst Science, Lengerich, Germany, 3rd edition, 2009.
  2. J. L. De Gennes, R. Touraine, B. Maunand, J. Truffert, and P. Laudat, “Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment,” Bulletins et Memoires de la Societe Medicale des Hopitaux de Paris, vol. 118, no. 15, pp. 1377–1402, 1967. View at Scopus
  3. G. R. Thompson, R. Lowenthal, and N. B. Myant, “Plasma exchange in the management of homozygous familial hypercholesterolaemia,” The Lancet, vol. 1, no. 7918, pp. 1208–1211, 1975. View at Scopus
  4. T. Agishi, J. Kaneko, Y. Hasuo, et al., “Double filtration plasmapheresis with no or minimal amount of blood derivate for substitution,” in Plasma Exchange, H. G. Sieberth, Ed., p. 53, Schattauer, Stuttgart, Germany, 1980.
  5. W. Stoffel and T. Demant, “Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 1, pp. 611–615, 1981. View at Scopus
  6. H. Borberg, W. Stoffel, and K. Oette, “The development of specific plasmaimmunoadsorption,” Plasma Therapy and Transfusion Technology, vol. 4, no. 4, pp. 459–466, 1983.
  7. H. Wieland and D. Seidel, “A simple specific method for precipitation of low density lipoproteins,” Journal of Lipid Research, vol. 24, no. 7, pp. 904–909, 1983. View at Scopus
  8. Y. Nose, M. Usami, and P. S. Malchesky, “Clinical thermofiltration: initial application,” Artificial Organs, vol. 9, no. 4, pp. 425–427, 1985. View at Scopus
  9. G. D. Antwiller, P. C. Dau, and D. D. Lobdell, “Treatment of familial hypercholesterolemia by precipitation of low density lipoproteins with dextran sulfate,” in Proceedings of the 1st International Congress of the World Apher Association, p. 68, 1985.
  10. H. Mabuchi, J. Michishita, T. Mitsuaki, et al., “A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continous apheresis),” Atherosclerosis, vol. 68, no. 1-2, pp. 19–25, 1987.
  11. T. Bosch, B. Schmidt, M. Blumenstein, and H. J. Gurland, “Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood,” Artificial Organs, vol. 17, no. 7, pp. 640–652, 1993. View at Scopus
  12. C. Otto, P. Kern, R. Bambauer, S. Kallert, P. Schwandt, and K. G. Parhofer, “Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia,” Artificial Organs, vol. 27, no. 12, pp. 1116–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Borberg, A. Gaczkowski, V. Hombach, K. Oette, and W. Stoffel, “Regression of atherosclerosis in patients with familial hypercholesterolaemia under LDL-apheresis,” Progress in Clinical and Biological Research, vol. 255, pp. 317–326, 1988. View at Scopus
  14. K. Oette and H. Borberg, “Variables involved in regression of atherosclerosis in familial hypercholesterolemic patients under long-term LDL-apheresis,” Plasma Therapy and Transfusion Technology, vol. 9, no. 1, pp. 17–23, 1988. View at Scopus
  15. W. O. Richter, K. Suhler, P. Schwandt, et al., “Extracorporeal LDL-elimination by immunoadsorption. Side effects and influences on other serum lipoproteins and serum parameters,” in Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease, A. M. Gotto, M. Manchini, W. O. Richter, et al., Eds., p. 183, Karger, Basle, Switzerland, 1990.
  16. R. Bambauer, H. E. Keller, R. Schiel, et al., “Three years experience with the Liposorber system in hyper-cholesterolemia,” in Therapeutic Plasmapheresis XII. VSP, T. Agishi, A. Kawamura, M. Mineshima, et al., Eds., p. 415, Tokyo, Japan, Utrecht, The Netherland, 1993.
  17. W. O. Richter, M. G. Donner, P. Schwandt, et al., “Long-term effects of LDL-apheresis on coronary heart disease,” Acta Oncologica, vol. 2, p. 147, 1996.
  18. T. Eisenhauer, P. Schuff-Werner, V. W. Armstrong, J. Talartschik, F. Scheler, and D. Seidel, “Long-term experience with the HELP system for treatment of severe familial hypercholesterolemia,” ASAIO Transactions, vol. 33, no. 3, pp. 395–397, 1987. View at Scopus
  19. J. Thiery, V. Armstrong, T. Bosch, et al., “Maximaltherapie der Hypercholesterinämie bei koronarer Herzkrankheit,” Therapiewoche, vol. 38, p. 3424, 1988.
  20. D. Seidel, V. W. Armstrong, P. Schuff-Werner, et al., “The HELP-apheresis multicenter study, an angiography assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart-disease,” European Journal of Clinical Investigation, vol. 21, no. 4, pp. 375–383, 1991.
  21. T. Bosch, B. Schmidt, M. Blumenstein, and H. J. Gurland, “Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood,” Artificial Organs, vol. 17, no. 7, pp. 640–652, 1993. View at Scopus
  22. P. Schuff-Werner, H. Golke, U. Bartmann, et al., “The HELP-study group: the HELP-LDL-apheresis multicenter study and angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease,” European Journal of Clinical Investigation, vol. 24, no. 11, pp. 724–732, 1994.
  23. B. R. Jaeger, B. Meiser, D. Nagel, et al., “Agrressive lowering of fibrinogen and cholesterol in prevention of graft vessel disease after heart transplantation,” Circulation, vol. 96, no. 9, supplement 2, pp. 154–158, 1997.
  24. K. P. Mellwig, D. Baller, U. Gleichmann et al., “Improvement of coronary vasodilatation capacity through single LDL apheresis,” Atherosclerosis, vol. 139, no. 1, pp. 173–178, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. M. G. Donner, K. G. Parhofer, W. O. Richter, and P. Schwandt, “Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis,” Metabolism, vol. 48, no. 7, pp. 881–886, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Schettler, H. Methe, P. Schuff-Werner, et al., “Acute effect of HELP treatment on radical scavering enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma,” European Journal of Clinical Investigation, vol. 30, no. 1, pp. 26–32, 2000.
  27. P. M. Moriarty, C. A. Gibson, J. Shih, and M. S. Matias, “C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis,” Atherosclerosis, vol. 158, no. 2, pp. 495–498, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. S. S. Wang, “Treatment and prophylaxis of cardiac allograft vasculopathy,” Transplantation Proceedings, vol. 40, no. 8, pp. 2609–2610, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. G. R. Thompson and K. Okabayashi, “Plasma exchange and LDL apheresis,” Progress in Clinical and Biological Research, vol. 255, pp. 311–316, 1988. View at Scopus
  30. B. R. Gordon, S. F. Kelsey, D. W. Bilheimer, et al., “for the lipsorber study group: treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system,” American Journal of Cardiology, vol. 70, p. 1010, 1992.
  31. H. Daida, Y. L. Lee, H. Yokai, et al., “Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis,” The American Journal of Cardiology, vol. 73, no. 15, pp. 1037–1040, 1994.
  32. A. A. Kroon, W. R. M. Aengevaeren, T. van der Werf et al., “LDL-apheresis atherosclerosis regression study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis,” Circulation, vol. 93, no. 10, pp. 1826–1835, 1996. View at Scopus
  33. B. R. Gordon and S. D. Saal, “Clinical experience and future directions for low-density lipoprotein apheresis in the United States,” Therapeutic Apheresis, vol. 1, no. 3, pp. 249–252, 1997. View at Scopus
  34. R. Bambauer, C. J. Olbricht, and E. Schoeppe, “Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results,” Therapeutic Apheresis, vol. 1, no. 3, pp. 242–248, 1997. View at Scopus
  35. H. Mabuchi, J. Koizumi, M. Shimizu, et al., “Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia,” The American Journal of Cardiology, vol. 82, no. 12, pp. 1489–1495, 1998.
  36. S. Nishimura, M. Sekiguchi, T. Kano et al., “Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan low-density lipoprotein apheresis coronary atherosclerosis prospective study (L-CAPS),” Atherosclerosis, vol. 144, no. 2, pp. 409–417, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. W. O. Richter, M. G. Donner, and P. Schwandt, “Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation,” Therapeutic Apheresis, vol. 3, no. 3, pp. 203–208, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Bambauer, R. Schiel, and R. Latza, “Low-density lipoprotein apheresis: an overview,” Therapeutic Apheresis, vol. 7, no. 4, pp. 382–390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Moriarty, R. Sosland, C. Gibson, and J. Belmont, “Comparison of different low density lipoprotein apheresis machines on brain natriuretic peptide levels in patients with familial hypercholesterolemia,” Therapeutic Apheresis and Dialysis, vol. 14, no. 1, pp. 74–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Szczepiorkowski, N. Bandarenko, H. C. Kim et al., “Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American society for apheresis,” Journal of Clinical Apheresis, vol. 22, no. 3, pp. 106–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. M. Szczepiorkowski, J. L. Winters, N. Banderenko, et al., “Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American society for apheresis,” Journal of Clinical Apheresis, vol. 25, no. 3, pp. 83–177, 2010.
  42. M. S. Brown and J. L. Goldstein, “Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic,” Journal of Clinical Investigation, vol. 72, no. 3, pp. 743–747, 1983. View at Scopus
  43. M. S. Brown and J. L. Goldstein, “How LDL receptors influence cholesterol and atherosclerosis,” Scientific American, vol. 251, no. 5, pp. 58–66, 1984. View at Scopus
  44. M. S. Brown and J. L. Goldstein, “A receptor-mediated pathway for cholesterol homeostasis,” Science, vol. 232, no. 4746, pp. 34–47, 1986. View at Scopus
  45. M. S. Brown and J. L. Goldstein, “Familial hypercholesterolemia: a genetic defect in the low density lipoprotein receptor,” The New England Journal of Medicine, vol. 294, no. 25, pp. 1386–1390, 1976. View at Scopus
  46. K. J. Williams, S. Vallabhajosula, I. U. Rahman et al., “Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 1, pp. 242–246, 1988. View at Scopus
  47. F. Bergesio, R. Ciuti, M. Salvadori et al., “Are lipid abnormalities reliable cardiovascular risk factors in dialysis patients?” International Journal of Artificial Organs, vol. 12, no. 11, pp. 667–682, 1989.
  48. European Atherosclerosis Society, “Strategies for prevention of coronary heart disease. A policy statement of the European atherosclerosis society,” European Heart Journal, vol. 8, no. 1, pp. 77–88, 1987.
  49. E. J. Schaefer, J. J. Genest, J. M. Ordovas, D. N. Salem, and P. W. F. Wilson, “Familial lipoprotein disorders and premature coronary artery disease,” Current Opinion in Lipidology, vol. 4, no. 4, pp. 288–298, 1993. View at Scopus
  50. D. M. Lee, “Isolation and characterization of low density lipoproteins,” in Low Density Lipoproteins, C. E. Day and R. S. Levy, Eds., p. 3, Plenum, New York, NY, USA, 1976.
  51. G. Assmann, H. Schulte, and A. von Eckadstein, “Epidemiological and clinical relevance of triglycerides and high density lipoprotein cholesterol,” Cardiovascular Risk Factors, vol. 5, p. 4, 1995.
  52. I. De Castro-Orós, M. Pocovi, and F. Civeira, “The genentic basic of familial hypercholesterolemia: inheritance, linkage, and mutations,” The Application of Clinical Genetics, vol. 3, pp. 53–54, 2010. View at Publisher · View at Google Scholar
  53. R. Bambauer, R. Schiel, and R. Latza, “Low-density lipoprotein apheresis: an overview,” Therapeutic Apheresis, vol. 7, no. 4, pp. 382–390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. US Department of Health Education and Welfare, “Report of the Working Group of Arteriosclerosis of the National Heart, Lung and Blood Institute,” Publ. no. (NIH) 82, Goverm Print Off, Washington, DC, USA, 1987.
  55. G. Assmann and H. Schulte, “Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience),” American Journal of Cardiology, vol. 70, no. 7, pp. 733–737, 1992. View at Publisher · View at Google Scholar · View at Scopus
  56. O. P. Heinonen, J. K. Huttunen, V. Minninen, et al., “The helsinki heart study: coronaria heart disease incidence during extended follow-up,” Journal of Internal Medicine, vol. 235, no. 1, pp. 41–49, 1994.
  57. Scandinavian Simvastatin Survival Group, “Randomized trial of cholesterol lowering in 444 patients with coronary heart disease. The scand. Simvastatin survival study (4s),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Publisher · View at Google Scholar
  58. J. K. Huttunen, V. Manninen, M. Manttari et al., “The helsinki heart study: central findings and clinical implications,” Annals of Medicine, vol. 23, no. 2, pp. 155–159, 1991. View at Scopus
  59. M. J. Stampfer, R. M. Krauss, J. Ma et al., “A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction,” Journal of the American Medical Association, vol. 276, no. 11, pp. 882–888, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Schiel, R. Bambauer, and U. Müller, “Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: four years' experience,” Artificial Organs, vol. 20, no. 4, pp. 318–323, 1996. View at Scopus
  61. A. Fernandez-Cruz, “New outlooks in the evalution of heart failure management and prognosis the emerging role of endothelin,” Cardiovascular Risk Factors, vol. 7, p. 1, 1997.
  62. J. Loscalzo and A. Sniderman, “Cardiovascular disease and hyperlipidaemia,” Current Opinion in Lipidology, vol. 4, no. 4, pp. 273–276, 1993. View at Scopus
  63. D. J. Stewart and J. C. Monge, “Hyperlipidemia and endothelial dysfunction,” Current Opinion in Lipidology, vol. 4, no. 4, pp. 319–324, 1993. View at Scopus
  64. S. Taddei, A. Virdis, L. Ghiadoni, et al., “Hypertension and endothelial dysfunction,” Cardiovascular Risk Factors, vol. 7, p. 76, 1997.
  65. G. M. Rubanyi, J. C. Guillaume, J. Revuz, et al., “The role of endothelium on cardiovascular homeostasis and diseases,” Journal of Cardiovascular Pharmacology, vol. 22, supplement 4, pp. S1–S14, 1994.
  66. V. Lahere, J. Navaaro-Cid, L. M. Ruilope, et al., “Ecdothelial dysfunction. Dyslipidemia and atherosclerosis: pathophysiologic and therapeutic implications,” Cardiovascular Risk Factors, vol. 7, p. 59, 1997.
  67. L. E. Spieker, I. Sudano, D. Hürlimann et al., “High-density lipoprotein restores endothelial function in hypercholesterolemic men,” Circulation, vol. 105, no. 12, pp. 1399–1402, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. R. F. Furchgott and P. M. Vanhoute, “Endothelium-derived relaxing factor and contraacting factor,” The FASEB Journal, vol. 3, no. 9, pp. 2007–2018, 1989.
  69. S. Moncada, R. M. J. Palmer, and E. A. Higgs, “Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacological Reviews, vol. 43, no. 2, pp. 109–142, 1991. View at Scopus
  70. J. Shepherd, S. M. Cobbe, I. Ford et al., “Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia,” The New England Journal of Medicine, vol. 333, no. 20, pp. 1301–1307, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. W. P. Castelli, R. J. Garrison, and P. W. F. Wilson, “Incidence of coronary heart disease and lipoprotein cholesterol levels. The framingham study,” Journal of the American Medical Association, vol. 256, no. 20, pp. 2835–2838, 1986. View at Scopus
  72. A. Leaf, “Management of hypercholesterolemia: are preventive interventions advisable?” The New England Journal of Medicine, vol. 321, no. 10, pp. 680–684, 1989. View at Scopus
  73. J. S. Yudkin, “How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects,” British Medical Journal, vol. 306, no. 6888, pp. 1313–1318, 1993. View at Scopus
  74. J. Shepherd and R. M. Krauss, “1. Pathophysiology of triglyceride-rich particles. A. Metabolism of triglyceride-rich particles,” American Journal of Cardiology A, vol. 68, no. 3, article 5, 1991. View at Scopus
  75. J. M. Gaziano, C. H. Hennekens, C. J. O'Donnell, J. L. Breslow, and J. E. Buring, “Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction,” Circulation, vol. 96, no. 8, pp. 2520–2525, 1997. View at Scopus
  76. M. R. Soma and R. Paoletti, “The future of cardiovascular disease prevention and the role of lipid regulation,” Cardiovascular Risk Factors, vol. 6, no. 5, pp. 262–268, 1996. View at Scopus
  77. A. Ceriello, C. Taboga, L. Tonutti et al., “Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment,” Circulation, vol. 106, no. 10, pp. 1211–1218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. A. J. Cohen and C. M. Kessler, “Acquired inhibitors,” Bailliere's Clinical Haematology, vol. 9, no. 2, pp. 331–354, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Nomura, T. Yamamura, A. Yamamoto et al., “The association between lipoprotein(a) and severity of coronary and cerebrovascular atherosclerosis, especially in non-hypercholesterolemic subjects,” Cardiovascular Risk Factors, vol. 3, no. 6, pp. 336–343, 1993. View at Scopus
  80. G. Uttermann, “Lipoprotein (a): a genetic risc factor for premature coronary heart disease,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 1, p. 7, 1991.
  81. M. Jauhiainen, P. Koskinen, C. Ehnholm et al., “Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki heart study participants,” Atherosclerosis, vol. 89, no. 1, pp. 59–67, 1991. View at Scopus
  82. A. M. Scanu and G. Fless, “Lipoprotein (a) heterogenicity and bilogical relevance,” The Journal of Clinical Investigation, vol. 85, no. 6, pp. 1709–1715, 1990. View at Publisher · View at Google Scholar
  83. A. L. White and R. E. Lanford, “Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 28716–28723, 1994. View at Scopus
  84. O. Wiklund, G. Fager, A. Andersson, U. Lundstam, P. Masson, and B. Hultberg, “N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels,” Atherosclerosis, vol. 119, no. 1, pp. 99–106, 1996. View at Publisher · View at Google Scholar · View at Scopus
  85. D. J. Grainger, H. L. Kirschenlohr, J. C. Metcalfe, P. L. Weissberg, D. P. Wade, and R. M. Lawn, “Proliferation of human smooth muscle cells promoted by lipoprotein(a),” Science, vol. 260, no. 5114, pp. 1655–1658, 1993. View at Scopus
  86. D. J. Grainger, P. R. Kemp, A. C. Liu, R. M. Lawn, and J. C. Metcalfe, “Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice,” Nature, vol. 370, no. 6489, pp. 460–462, 1994. View at Publisher · View at Google Scholar · View at Scopus
  87. W. Y. Craig, L. M. Neveux, G. E. Palomaki, M. M. Cleveland, and J. E. Haddow, “Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies,” Clinical Chemistry, vol. 44, no. 11, pp. 2301–2306, 1998. View at Scopus
  88. M. Sandkamp, H. Funke, H. Schulte, E. Kohler, and G. Assmann, “Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age,” Clinical Chemistry, vol. 36, no. 1, pp. 20–23, 1990. View at Scopus
  89. G. Alfthan, J. Pekkanen, M. Jauhiainen et al., “Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study,” Atherosclerosis, vol. 106, no. 1, pp. 9–19, 1994. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Tsimikas, E. S. Brilakis, E. R. Miller et al., “Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease,” The New England Journal of Medicine, vol. 353, no. 1, pp. 46–57, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. J. W. Gaubatz, R. C. Hoogeven, A. S. Hoffmann, et al., “Isolation, quatitation and characterization of a stable complex formed by Lp(a) binding to triglycerides-rich lipoprotein,” The Journal of Lipid Research, vol. 42, no. 12, pp. 2058–2068, 2001.
  92. N. Komai, R. Morishita, S. Yamada et al., “Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells,” Hypertension, vol. 40, no. 3, pp. 310–314, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Seed, F. Hoppichler, D. Reaveley et al., “Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia,” The New England Journal of Medicine, vol. 322, no. 21, pp. 1494–1499, 1990. View at Scopus
  94. P. M. Riedker, C. H. Hennekens, and M. J. Stamper, “A prospective study of lipoprotein (a) and the risk of myocardial infarction,” JAMA, vol. 270, no. 18, pp. 2195–2199, 1993. View at Publisher · View at Google Scholar
  95. J. Ducas, C. Siversides, T. C. Dembinski, et al., “Apolipoprotein (a) phenotype and lipoprotein (a) level predict peritoneal dialysis patient mortality,” Peritoneal Dialysis International, vol. 22, no. 4, pp. 492–499, 2002.
  96. F. Kronenberg, G. Utermann, and H. Dieplinger, “Lipoprotein(a) in renal disease,” American Journal of Kidney Diseases, vol. 27, no. 1, pp. 1–25, 1996. View at Scopus
  97. L. A. Sechi, L. Zingaro, C. Catena, A. Perin, S. De Marchi, and E. Bartoli, “Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure,” Kidney International, vol. 56, no. 3, pp. 1049–1057, 1999. View at Publisher · View at Google Scholar · View at Scopus
  98. A. A. Ariyo, C. Thach, and R. Tracy, “Lp(a) lipoprotein, vascular disease, and mortality in the elderly,” The New England Journal of Medicine, vol. 349, no. 22, pp. 2108–2115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. A. A. Kroon, P. N. Demacker, and A. F. Stalenhoef, “N-acetylcysteine and serum concentrations of lipoprotein(a),” Journal of Internal Medicine, vol. 230, no. 6, pp. 519–526, 1991. View at Scopus
  100. H. Ullrich, K. J. Lackner, and G. Schmitz, “Lipoprotein(a) apheresis in severe coronary heart disease: an immunoadsorption method,” Artificial Organs, vol. 22, no. 2, pp. 135–139, 1998. View at Publisher · View at Google Scholar · View at Scopus
  101. A. F. Rosenthal, J. Ginsburg, and F. Crawford, “Homocysteine and heart disease in dialysis patients,” Dialysis and Transplantation, vol. 27, no. 10, pp. 627–629, 1998. View at Scopus
  102. S. Biasioli and R. Schiavon, “Homocysteine as a cardiovascular risk factor,” Blood Purification, vol. 18, no. 3, pp. 177–182, 2000. View at Scopus
  103. S. H. Mudd, H. L. Levy, and F. Skovby, “Disorders of transsulfuration,” in The Metabolic and Molecular Bases of Herited Diseases, C. R. Scriver, A. L. Beaucher, W. S. Sly, et al., Eds., p. 1279, Mc Graw-Hill, New York, NY, USA, 1995.
  104. M. Lilien, M. Duran, K. van Hoeck, B. T. Poll-The, and C. Schröder, “Hyperhomocyst(e)inaemia in children with chronic renal failure,” Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 366–368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  105. D. S. Parsons, D. A. Reaveley, D. V. Pavitt, and E. A. Brown, “Relationship of renal function to homocysteine and lipoprotein(a) levels: the frequency of the combination of both risk factors in chronic renal impairment,” American Journal of Kidney Diseases, vol. 40, no. 5, pp. 916–923, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. European Atherosclerosis Society (Study Group), “Strategies for prevention of coronary heart disease: a policy statement of the European atherosclerosis society,” European Heart Journal, vol. 8, no. 1, pp. 77–88, 1990.
  107. D. W. Bilheimer, J. L. Goldstein, and S. M. Grundy, “Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia,” The New England Journal of Medicine, vol. 311, no. 26, pp. 1658–1664, 1984. View at Scopus
  108. M. L. Berger, H. M. Wilson, and C. L. Liss, “A comparison of the tolerability and efficacy of lovastatin 20 and fluvastatin 20 mg in the treatment of primary hypercholesterolemia,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 1, no. 2, pp. 101–106, 1996. View at Publisher · View at Google Scholar
  109. C. Guijaro and J. Egido, “Modulation of the mevalonate pathway: potential mechanisms od vascular protection by HMG-CoA reductase inhibitors independent of cholesterol reduction,” Cardiovascular Risk Factors, vol. 29, 1997.
  110. D. R. Illingworth, E. A. Stein, R. H. Knopp, et al., “A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 1, no. 1, pp. 23–29, 1996. View at Publisher · View at Google Scholar
  111. C. B. Treasure, J. L. Klein, W. S. Weintraub et al., “Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease,” The New England Journal of Medicine, vol. 332, no. 8, pp. 481–487, 1995. View at Publisher · View at Google Scholar · View at Scopus
  112. P. B. Duell, W. E. Connor, and D. R. Illingworth, “Rhabdomyolysis after taking Atorvastatin with Gemfibrozil,” American Journal of Cardiology, vol. 81, no. 3, pp. 368–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Bo, F. Bonino, M. Neirotti et al., “Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs,” Angiology, vol. 42, no. 2, pp. 106–113, 1991. View at Scopus
  114. W. B. Kannel, P. A. Wolf, W. P. Castelli, and R. B. D'Agostino, “Fibrinogen and risk of cardiovascular disease. The framingham study,” Journal of the American Medical Association, vol. 258, no. 9, pp. 1183–1186, 1987. View at Scopus
  115. P. L. Malini, E. Ambrosioni, O. De Divitiis, S. Di Somma, G. Rosiello, and B. Trimarco, “Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia,” Clinical Therapeutics, vol. 13, no. 4, pp. 500–510, 1991. View at Scopus
  116. E. Reihner, M. Rudling, D. Stahlberg et al., “Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol,” The New England Journal of Medicine, vol. 323, no. 4, pp. 224–228, 1990. View at Scopus
  117. J. Thiery, C. Creutzfeldt, W. Creutzfeldt, A. K. Walli, and D. Seidel, “Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia,” Klinische Wochenschrift, vol. 68, no. 16, pp. 814–822, 1990. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Yamamoto, A. Kawaguchi, M. Harada-Shiba, M. Tsushima, and S. I. Kojima, “Apheresis technology for prevention and regression of atherosclerosis: an overview,” Therapeutic Apheresis, vol. 1, no. 3, pp. 233–241, 1997. View at Scopus
  119. Scandinavian Simvastatin Survival Study Group, “Design and baseline results of the Scandinavian simvastatin surviavl study of patients with stable angina and/or previous myocardial infarction,” American Journal of Cardiology, vol. 71, no. 5, pp. 393–400, 1993.
  120. R. Candrina, S. Spandrio, O. Stefano et al., “Double-filtration plasmapheresis in heterozygous familial hypercholesterolemia: our experience over 25 treatments,” Beitrage zur Infusionstherapie, vol. 23, pp. 189–190, 1988. View at Scopus
  121. G. R. Thompson and K. Okabayashi, “Plasma exchange and LDL apheresis,” Progress in Clinical and Biological Research, vol. 255, pp. 311–316, 1988. View at Scopus
  122. K. Tojo, S. Sakai, and T. Miyahara, “Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS),” Nihon Jinzo Gakkai, vol. 30, no. 9, pp. 1153–1160, 1988. View at Scopus
  123. A. Yamamoto, S. Yokoyama, M. Satani, T. Kikkawa, and B. Kishino, “Evaluation of selective LDL-removal in the treatment of familial hypercholesterolemia: double membrane filtration and adsorption system,” Progress in Clinical and Biological Research, vol. 255, pp. 357–366, 1988. View at Scopus
  124. S. Sakata, T. Komaki, and N. Kojima, “Dynamics of plasma lipoproteins and lipids during double filtration plasmapheresis (HDFP),” Japanese Journal of Medicine, vol. 26, no. 2, pp. 176–179, 1987. View at Scopus
  125. E. B. Smith and L. Crosbie, “Fibrinogen and fibrin in atherogenesis,” in Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease, A. M. Gotto, M. Manchini, W. O. Richter, et al., Eds., p. 4, Karger, Basle, Switzerland, 1990.
  126. H. C. Geiss, K. G. Parhaofer, M. Donner, et al., “Low-density lipoprotein apheresis by membrane differential filtration (cascade filtration),” Therapeutic Apheresis and Dialysis, vol. 3, no. 3, pp. 199–202, 1993.
  127. R. Klingel, P. Mausfeld, C. Fassbender, and B. Goehlen, “Lipidfiltration—safe and effective methodology to perform lipid-apheresis,” Transfusion and Apheresis Science, vol. 30, no. 3, pp. 245–254, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. R. Klingel, T. Fassbender, C. Fassbender, and B. Göhlen, “From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis,” Therapeutic Apheresis, vol. 7, no. 3, pp. 350–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Hibino, YK Seok, H. Tsuda, et al., “Effect of double filtration plasmapheresis (HDFPP) in male patients with borderline hyper-LDL-cholesterolemia: lipid removal and inflammation suppreesion,” Anti-Aging Medicine, vol. 6, pp. 32–40, 2009.
  130. R. Klingel, C. Fassbenderm, T. Fassbender, et al., “Rheopheresis: rheologic, functional, and structural aspects,” Therapeutic Apheresis and Dialysis, vol. 4, no. 5, pp. 348–357, 2000.
  131. R. Klingel, B. Erdtracht, V. Gauss, A. Piazolo, P. Mausfeld-Lafdhiya, and C. Diehm, “Rheopheresis in patients with critical limb ischemia—results of an open label prospective pilot trial,” Therapeutic Apheresis and Dialysis, vol. 9, no. 6, pp. 473–481, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. N. Terai, U. Julius, M. Haustein, et al., “The effect of low-density lipoprotein apheresis on ocular microcirculation in patients with hypercholesterolemia: a pilot study,” British Journal of Ophthalmology, vol. 95, pp. 401–404, 2010. View at Publisher · View at Google Scholar
  133. W. Stoffel and T. Demant, “Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 1, pp. 611–615, 1981. View at Scopus
  134. M. Parusel, J. G. Kadar, H. Hermann, et al., Anaphytoxin generation and complement changes during clinically uneventful specific immunoadsorption (LDL apheresis) therapies Abstract Book, Munich, Germany, p. 12, 1989.
  135. I. S. Jovin, U. Taborski, and G. Müller-Berghaus, “Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis,” ASAIO Journal, vol. 46, no. 3, pp. 298–300, 2000. View at Scopus
  136. R. Bambauer, R. Schiel, R. Latza, et al., “Current topics on low-density lipoprotein apheresis methods,” Therapeutic Apheresis and Dialysis, vol. 5, no. 4, pp. 293–300, 2001.
  137. H. Borberg, “Results of an open, longitudinal multicenter LDL-apheresis trial,” Transfusion Science, vol. 20, no. 1, pp. 83–94, 1999. View at Publisher · View at Google Scholar · View at Scopus
  138. H. Ullrich, B. Mansouri-Taleghani, K. J. Lackner, B. Schalke, U. Bogdahn, and G. Schmitz, “Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment,” Transfusion Science, vol. 19, pp. 33–38, 1998. View at Publisher · View at Google Scholar · View at Scopus
  139. G. M. Kostner and F. Krempler, “Lipoprotein (a),” Current Opinion in Lipidology, vol. 3, pp. 279–284, 1992.
  140. S. N. Pokrovsky, I. Y. Adamova, O. Y. Afanasieva, and G. F. Benevolenskaya, “Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study,” Artificial Organs, vol. 15, no. 2, pp. 136–146, 1991. View at Scopus
  141. S. N. Pokrovsky, A. V. Sussekov, O. I. Afanasieva, I. Y. Adamova, A. A. Lyakishev, and V. V. Kukharchuk, “Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data,” Chemistry and Physics of Lipids, vol. 67-68, pp. 323–330, 1994. View at Publisher · View at Google Scholar · View at Scopus
  142. D. Seidel and H. Wieland, “Ein neues verfahren zur selektiven messung und extrakorporalen elimination von low-density-lipoproteinen,” Journal of Clinical Chemistry & Clinical Biochemistry, vol. 20, p. 684, 1982.
  143. T. Eisenhauer, V. W. Armstrong, E. Koren, et al., “Heparin extracorporeal LDL-precipitation (HELP): technical aspects and influence on plasma lipoproteins and apolipoproteins,” in Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease, A. M. Gotto, M. Manchini, W. O. Richter, et al., Eds., p. 3, Karger, Basle, Switzerland, 1976.
  144. F. Ruschitzka, G. Noll, T. F. Lüscher, et al., “The influence of heparin-induced extracorporeal LDL precititation (HELP) on the endothelium function of patients with coronary heart disease and hypercholesterolemia,” Lip Journal, vol. 8, p. 24, 1999.
  145. P. Schuff-Werner, “Heparin-induzierte extrakorporale LDL-Präzipitation (HELP) bei therapie-refraktärer Hypercholesterolemie und kornarer Herkrankheit: Einfluß auf die klinische und morphologische Regression der Koronarsklerose,” Zs Kardiologie, vol. 86, supplement 1, p. 57, 1997.
  146. V. W. Armstrong, D. Niedmann, T. Eisenhauer et al., “Acute and long-term effects of low-density lipoprotein apheresis on the serum concentrations of vitamins E and A,” Klinische Wochenschrift, vol. 66, no. 3, pp. 123–128, 1988. View at Scopus
  147. J. Thiery and D. Seidel, “Safety and effectiveness of long-term LDL-apheresis in patients at high risk,” Current Opinion in Lipidology, vol. 9, no. 6, pp. 521–526, 1998. View at Publisher · View at Google Scholar · View at Scopus
  148. C. Otto, H. C. Geiss, K. Empen, and K. G. Parhofer, “Long-term reduction of C-reactive protein concentration by regular LDL apheresis,” Atherosclerosis, vol. 174, no. 1, pp. 151–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  149. Y. Wang, F. Blessing, A. K. Walli, P. Überfuhr, P. Fraunberger, and D. Seidel, “Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins—reduction of circulating proinflammatory and procoagulatory markers,” Atherosclerosis, vol. 175, no. 1, pp. 145–150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. B. R. Jaeger, P. Marx, T. Pfefferkorn, et al., “Heparin—mediated extracorporeal LDL/fibronogen precipitation—HELP—in coronary and cerebral ischemia,” Acta Neurochirurgica, vol. 73, pp. 81–84, 1999.
  151. J. W. Park, C. Mrowietz, S. Schüler, et al., “Cutaneous microcirculation in cardiac allograft recipients with severe hypercholesterolemia before, during, and after the first HELP apheresis,” Applied Cardiopulmonary Pathophysiology, vol. 9, p. 19, 2000.
  152. G. Baggio, L. Previato, C. Corti, et al., “LDL-apheresis with HELP system: a 16 month study in severe hypercholesterolemic patients with ischemic heart disease,” Beitr Infusionsther, vol. 23, pp. 146–151, 1988.
  153. M. Suckfüll, J. Thiery, and K. Schorn, “Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: a prospective, randomised study,” Acta Oto-Laryngologica, vol. 119, no. 7, pp. 763–766, 1999.
  154. G. Bianchin, G. Russi, N. Romano, and P. Fioravanti, “Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study,” Laryngoscope, vol. 120, no. 4, pp. 800–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  155. T. Agishi, W. Wood, and B. Gordon, “LDL apheresis using the Liposorber® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia,” Current Therapeutic Research, vol. 55, no. 8, pp. 879–904, 1994. View at Publisher · View at Google Scholar · View at Scopus
  156. W. Knisel, M. Muller, I. Besenthal et al., “Application of a new LDL apheresis system using two dextran sulfate cellulose columns in combination with an automatic column-regenerating unit and a blood cell separator,” Journal of Clinical Apheresis, vol. 6, no. 1, pp. 11–15, 1991. View at Scopus
  157. N. Tani, “Development of selective low-density lipoprotein (LDL) apheresis system: immobilized polyanion as LDL-specific adsorption for LDL apheresis system,” Artificial Organs, vol. 20, no. 8, pp. 922–929, 1996. View at Scopus
  158. S. Kojima, M. Harada-Shiba, Y. Toyoto, et al., “Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis,” The International Journal of Artificial Organs, vol. 15, no. 3, pp. 185–190, 1992.
  159. E. A. Burgstaler and A. A. Pineda, “Plasma exchange versus an affinity column for cholesterol reduction,” Journal of Clinical Apheresis, vol. 7, no. 2, pp. 69–74, 1992. View at Publisher · View at Google Scholar · View at Scopus
  160. H. Mabuchi, J. Koizumi, I. Michishita, et al., “Effects on coronary atherosclerosis of long-term treatment of familial hypercholesterolemia by LDL-apheresis,” Beitr Infusionsther, vol. 23, p. 87, 1988.
  161. S. Teschner, C. Kurschat, and V. Burst, “Therapeutic apheresis in transplantation: overview and critical evalutation of available modalities in respect to indications, evidence and costs,” Transpalntationsmedizin, vol. 22, no. 4, pp. 226–272, 2010.
  162. A. A. Kroon, D. W. Swinkels, P. W. J. van Dongen, and A. F. H. Stalenhoef, “Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis,” Metabolism, vol. 43, no. 9, pp. 1164–1170, 1994. View at Publisher · View at Google Scholar · View at Scopus
  163. C. Stefanutti, A. Notarbartolo, V. Collridi, et al., “LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.,” Artificial Organs, vol. 21, no. 10, pp. 1126–1127, 1997. View at Publisher · View at Google Scholar
  164. N. Koga, Y. Iwata, and A. Yamamoto, “Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment,” Artificial Organs, vol. 16, no. 2, pp. 171–176, 1992. View at Scopus
  165. K. Kajinami and H. Mabuchi, “Therapeutic effects of LDL apheresis in the prevention of atherosclerosis,” Current Opinion in Lipidology, vol. 10, no. 5, pp. 401–406, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Tridon, J. B. Palcoux, P. Jouanel, M. J. Bezou, M. Coulet, and G. Betail, “Complement activation during low-density lipoprotein apheresis,” Artificial Organs, vol. 16, no. 6, pp. 577–585, 1992. View at Scopus
  167. A. Yamamoto, S. Kojima, M. Shiba-Harada, A. Kawaguchi, and K. Hatanaka, “Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column,” Artificial Organs, vol. 16, no. 2, pp. 177–181, 1992. View at Scopus
  168. F. Cambien, O. Poiser, L. Lecerf, et al., “Delection polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction,” Nacture, vol. 359, pp. 641–644, 1992. View at Publisher · View at Google Scholar
  169. C. J. Olbricht, D. Schaumann, and D. Fischer, “Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors,” The Lancet, vol. 340, no. 8824, pp. 908–909, 1992. View at Scopus
  170. C. A. Dinarello, “ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis (I),” The Lancet, vol. 337, no. 8737, p. 370, 1991. View at Scopus
  171. D. A. Pegues, C. M. Beck-Sague, and S. W. Woolen, “Anaphylatoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE-inhibitors,” Kidney International, vol. 42, no. 5, pp. 1232–1237, 1992.
  172. S. Kojima, M. Harada-Shiba, Y. Toyoto, et al., “Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis,” The International Journal of Artificial Organs, vol. 15, no. 3, pp. 185–190, 1992.
  173. D. H. Krieter, J. Steinke, M. Kerkhoff et al., “Contact activation in low-density lipoprotein apheresis systems,” Artificial Organs, vol. 29, no. 1, pp. 47–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. T. Bosch, J. Thiery, H. J. Gurland, et al., “Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL apheresis and hemodialysis in patients with hypercholesterolemia and endstage renal failure,” Nephrology Dialysis Transplantation, vol. 8, no. 12, pp. 1350–1358, 1993.
  175. T. Bosch, B. Schmidt, W. Kleophas, et al., “LDL-hemoperfusion—a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patirents,” Artificial Organs, vol. 21, no. 10, pp. 1060–1065, 1993.
  176. T. Bosch, A. Lnnertz, B. Schmidt, et al., “Dali apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoprotein from whole blood,” Artificial Organs, vol. 24, no. 2, pp. 81–90, 2000. View at Publisher · View at Google Scholar
  177. T. Bosch, B. Schmidt, W. Kleophas, et al., “Clinical efficacy and biocompatibility of the first LDL-adsorber compatible with human blood,” The International Journal of Artificial Organs, vol. 18, p. 417, 1995.
  178. L. J. Dräger, U. Julius, K. Kraezle, et al., “Dali-the first human blood low-density lipoprotein and lipoprotein (a) system in a clinical use: procedure and clinical results,” European Journal of Clinical Investigation, vol. 28, no. 12, pp. 994–1002, 1998.
  179. T. Bosch, S. Gahr, U. Belchner, et al., “Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions,” Therapeutic Apheresis and Dialysis, vol. 10, no. 3, pp. 210–218, 2006.
  180. H. Tasaki, K. Yamashita, Y. Saito et al., “Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial,” Therapeutic Apheresis and Dialysis, vol. 10, no. 1, pp. 32–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  181. J. Streicher, P. Valent, H. Schmidt, et al., “Up-regulation of LDL-immunopheresis in patients with familial hyperchoelesterolemia,” Journal of Investigative Medicine, vol. 47, p. 378, 1999.
  182. S. Tselmin, G. Schmitz, U. Julius, et al., “Acute effects of lipid apheresis on human nserum lipidome,” Atherosclerosis, vol. 10, no. 5, pp. 27–33, 2009.
  183. “Apherese Standard der deutschen Arbeitsgemeinschaft für klinische Nephrologie e.V.,” Mitt Klin Nephrol XXXI, vol. 31, no. 1, p. 103, 2002.